Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities (2021 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Gains from Investment Securities of -$228965.0 for Q1 2026, down 390.71% sequentially from -$46660.0 in Q4 2025, and down 609.08% YoY from $44976.0 in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Gains from Investment Securities for 6 years, with the latest figure at -$228965.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 609.08% year-over-year to -$228965.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$227372.0 (up 80.82% YoY) and the FY2025 annual result came in at $46569.0, up 103.19% from the prior year.
- Gains from Investment Securities eased to -$228965.0 in Q1 2026 per CPIX's latest filing, from -$46660.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $370464.0 in Q1 2022 and troughed at -$1.0 million in Q4 2022.
- A 5-year average of -$293255.1 and a median of -$230430.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities surged 119.52% in 2025, then slumped 609.08% in 2026.
- Over 5 years, Gains from Investment Securities stood at -$1.0 million in 2022, then soared by 77.22% to -$236128.0 in 2023, then sank by 122.22% to -$524732.0 in 2024, then jumped by 91.11% to -$46660.0 in 2025, then sank by 390.71% to -$228965.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$228965.0, -$46660.0, and $9651.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Cumberland Pharmaceuticals | 114.68 Mn | 110.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -228,965.00 |
| Mar 31, 2026 | -228,965.00 |
| Dec 31, 2025 | -46,660.00 |
| Dec 31, 2025 | -46,660.00 |
| Sep 30, 2025 | 9,651.00 |
| Sep 30, 2025 | 9,651.00 |
| Jun 30, 2025 | 38,602.00 |
| Jun 30, 2025 | 38,602.00 |
| Mar 31, 2025 | 44,976.00 |
| Mar 31, 2025 | 44,976.00 |
| Dec 31, 2024 | -524,732.00 |
| Dec 31, 2024 | -524,732.00 |
| Sep 30, 2024 | -493,751.00 |
| Sep 30, 2024 | -493,751.00 |
| Jun 30, 2024 | -211,891.00 |
| Jun 30, 2024 | -211,891.00 |
| Mar 31, 2024 | -230,430.00 |
| Mar 31, 2024 | -230,430.00 |
| Dec 31, 2023 | -236,128.00 |
| Dec 31, 2023 | -236,128.00 |